Evidence map›Paper›PMID 32685896›Full record

ArticleResearch and practice in thrombosis and haemostasis2020

Pulmonary embolism in acute lymphoblastic leukemia - An observational study of 1685 patients treated according to the NOPHO ALL2008 protocol.

Ruta Tuckuviene, Cecilie Lundgaard Bjerg, Olafur Gisli Jonsson, Satu Langstrom, Cecilie Utke Rank, Susanna Ranta, Kadri Saks, Sonata Saulyte Trakymiene, Ellen Ruud

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 7 countries.

Ruta TuckuvieneDepartment of Pediatrics Aalborg University Hospital Aalborg Denmark.
Cecilie Lundgaard BjergDepartment of Pediatrics Aalborg University Hospital Aalborg Denmark.
Olafur Gisli JonssonChildren's Hospital Landspitali, University Hospital Reykjavik Iceland.
Satu LangstromDivision of Hematology-Oncology and Stem Cell Transplantation New Children's Hospital and Helsinki University Central Hospital University of Helsinki Helsinki Finland.
Cecilie Utke RankPediatric Oncology Research Laboratory and Department of Hematology Rigshospitalet University of Copenhagen Copenhagen Denmark.
Susanna RantaDepartment of Women's and Children's Health Karolinska University Hospital, and Childhood Cancer Research Unit Women's and Children's Health Karolinska Institutet Stockholm Sweden.
Kadri SaksDepartment of Oncohematology Tallinn Children's Hospital Tallinn Estonia.
Sonata Saulyte TrakymieneClinic of Children's diseases Faculty of Medicine Vilnius University Vilnius Lithuania.
Ellen RuudDepartment of Pediatric Hematology and Oncology Unit for Pediatric and Adolescent Medicine Oslo University Hospital Oslo Norway.
Aalborg University Hospital · DKHelsinki University Hospital · FIKarolinska Institutet · SENational University Hospital of Iceland · ISTallinn Health Care College · EEUniversity of Copenhagen · DKUniversity of Oslo · NOVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary embolism (PE) is a serious complication of acute lymphoblastic leukemia (ALL). We examined the cumulative incidence and clinical presentation of PE in a well-defined cohort of patients with ALL aged 1-45 years treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.

methodsAs part of the mandatory toxicity reporting of NOPHO ALL2008, thromboembolism including PE was reported consecutively. The cumulative incidence of first-time PE was calculated using the Aalen-Johansen estimator during a 2.5-year period from ALL diagnosis. We used Fisher's exact test to examine categorical variables and Cox logistic regression to estimate hazard ratios (HRs) for PE.

resultsPE was diagnosed in 32 of 1685 patients. The 2.5-year cumulative incidence of first-time PE increased with age: 0.43% (95% CI, 0.18-1.03) in children aged 1-9 years, 3.28% (95% CI, 1.72-6.22) in children aged 10-17 years, and 7.22% (95% CI, 4.61-11.21) in adults aged 18-45 years. The majority of PEs, 78% (25/32), occurred during asparaginase treatment. HRs adjusted for age and sex were associated with male sex (HR, 2.4; 95% CI, 1.0-5.6) and older age (10-17 years: HR 7.5; 95% CI, 2.5-22.2), 18-45 years: HR, 16.5; 95% CI, 6.1-44.5). In two-thirds of the patients (63%; 17/27), PE and its treatment had no impact on the administered doses of asparaginase. PE-associated 30-day mortality was 9.4% (95% CI, 1.9-25.0).

conclusionsAwareness of PE is warranted during ALL treatment. Larger multicenter studies are needed to examine predictors of PE in ALL.

Indexed as

acute lymphoblastic leukemiaasparaginaseincidencepulmonary embolismtoxicity

Identifiers

PMID32685896
PMCPMC7354408
OpenAlexW3035918634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.